X

Trial Profile

Multicenter Phase II Study of Apatinib in Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivoceranib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use

Most Recent Events

20 Jan 2020 Status changed from active, no longer recruiting to completed, according to results presented at the 42nd Annual San Antonio Breast Cancer Symposium
14 Dec 2019 Results assessing whether apatinib is effective for breast cancer with a chest wall metastasis were presented at the 42nd Annual San Antonio Breast Cancer Symposium
13 Sep 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com